Lefradafiban

DB04863InvestigationalSmall molecule

Lefradafiban is an oral platelet glycoprotein IIb/IIIa receptor antagonist being investigated in the treatment of angina.

Mechanism: GPIIb/IIIa inhibitors, such as lefradafiban, block the final common pathway of platelet aggregation.
Curator reviewed
Primary indication: For the treatment of unstable angina.Curator reviewed
Formula / weight: C₂₃H₂₅N₃O₆ · 439.4611 g/mol (avg)
Code names: FP-007SE

Resolves to

Compound

Structure

InChIKeyPGCFXITVMNNKON-ROUUACIJSA-NSMILES[H][C@@]1(COC2=CC=C(C=C2)C2=CC=C(C=C2)C(=N)NC(=O)OC)C[C@@H](CC(=O)OC)C(=O)N1

Targets

What you can answer from here — as of August 26, 2024

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

3Drug interactionsStructured to mechanism, not free text

1Clinical trialPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Lefradafiban, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.